30 Background: The Office of High Cost of the Colombian Health Ministry created the National Administrative Cancer Registry (NACR) in 2015 to obtain nationwide cancer data to find areas for improvement in cancer delivery. From initial data, a collaboration of healthcare experts identified 16 disease management indicators in gastric cancer (GC) in Colombia. In this study, we look at 2017 NACR data to investigate significant findings. Methods: We obtained NACR data compiled from the Department of Health Ministry from January 2, 2016- January 1, 2017 consisting of 32 departments and 1,122 municipalities. The 2017 NACR data for GC includes 13 of the 16 updated disease management indicators—time to diagnosis, percentage of patients with gastric cancer in situ, proportion of new cases identified in early stages, proportion of patients with TNM staging, time before treatment, time between neoadjuvant therapy and surgery, time between surgery and adjuvant therapy, proportion of stage 0-III patients receiving surgery with curative intent, proportion with nutrition support, proportion of surgical patients with nutrition support, mortality rate, and incidence. Results: The incidence of GC was 3.6 cases per 100,000 people and mortality was 3.6 cases per 100,000 people. The time to diagnosis was on average 43.7 days. 6.9% of stageable GC cases were in situ. 25.6% of cases were identified in early stages, and 50.7% of cases had TNM staging. The time to initial treatment was 60.3 days. The time between neoadjuvant therapy and surgery was 109.6 days and the time between surgery and adjuvant therapy was 75.5 days. 25.9% of stage 0-III patients received surgery with curative intent. 16.3% of GC patients received nutritional support along with 15.2% of surgical GC patients. Conclusions: Updated NACR data show long wait times for patients needing neoadjuvant or adjuvant therapies suggesting improvement in follow-up management. The low percentage of patients with nutritional support shows the need for supportive services. There should be strategies for earlier diagnosis given the low percentage of patients identified at early stages. Further directions include 2 and 5 year survival data and data on interdisciplinary care.